Kindstar Global

Kindstar Global Specialty Testing Group (hereinafter referred to as "Kindstar Global") is the first and largest high-end medical specialty testing service group in China. Kindstar Global is committed to leading the advancement of specialty testing technology and services in China, aiming to promote the development of specialized diagnosis and treatment and personalized medicine in China. Adhering to the principle of putting patients' interests first and doctors' needs foremost, Kindstar Global follows international norms, standards, and industry guidelines, introducing and developing the world's most advanced technologies and specialty testing methods. It provides comprehensive, advanced, and accurate specialty testing services to large tertiary hospitals, specialized hospitals, and general hospitals across China. The core members of the group's entrepreneurial and management team have all worked in the American academic and industrial sectors for over ten years, possessing broad vision and rich experience. The group has received capital support of tens of millions of dollars from world-renowned and largest venture capital funds such as Kleiner Perkins Caufield & Byers (KPCB), Morningside Venture Capital, China Internet Investment, and Baird Capital. On June 27, 2011, the Mayo Clinic in the United States announced the official signing of a multi-year strategic cooperation agreement with China Kindstar Global Specialty Testing Group. Mayo Clinic invested in Kindstar Global and, through its Department of Laboratory Medicine and Pathology and its Mayo Medical Laboratories, provided Kindstar Global with nearly 3,000 professional testing technologies, laboratory quality management, international accreditation standards, information consultation, standard operating procedures (SOPs), and methodological technologies, assisting Kindstar Global in accelerating the development of its high-quality specialty testing services in China and promoting the improvement of medical diagnosis and treatment levels in China.
Kindstar Global has established and is building a total of 38,000 square meters of national-level clinical testing, scientific research cooperation, and application development centers in Beijing, Shanghai, and Wuhan, equipped with internationally advanced facilities. It possesses dozens of technology platforms and professional laboratories, including high-resolution flow cytometry, multi-color flow cytometry cell sorting and cell culture, multi-color fluorescence real-time immature cell scanning imaging, second-generation genomics sequencing, gene chips, automated DNA/RNA extraction, COBAS high-sensitivity viral load systems, high-precision mass spectrometry, mass spectrometry chips, high-performance liquid/gas chromatography, molecular cellular, genetic and automated karyotype scanning, denaturing high-performance liquid chromatography, molecular pathology, digital pathology, liquid chips, single-molecule digital immunoassays, immunohistochemistry, protein fingerprinting, laser confocal microscopy, and electron microscopy. These facilities provide over 3,000 high-precision diagnostic tests in the fields of hematology, oncology, genetics, cardiovascular and cerebrovascular diseases, infectious diseases, autoimmune diseases, and in specialties including internal medicine, surgery, gynecology, and pediatrics, serving more than 3,000 hospitals in 31 provinces and municipalities directly under the central government and over 600 cities, especially over 1,000 large tertiary hospitals. Additionally, through cooperation with world-leading medical technology institutions and large pharmaceutical companies, Kindstar Global provides clinical research, drug trials, and translational medicine research services to clinical physicians nationwide.